US Codex
Bill
Notes

Cannabidiol and Marihuana Research Expansion Act

S. 253 · 117th Congress · Mar 24, 2022 · Lineage

AN ACT

To expand research on the cannabidiol and marihuana.

Section 1 Short title; table of contents

(a)
Short title— This Act may be cited as the “Cannabidiol and Marihuana Research Expansion Act”.
(b)
Table of contents— The table of contents for this Act is as follows:

Sec. 2 Definitions

In this Act—
(1)
the term appropriately registered means that an individual or entity is registered under the Controlled Substances Act (21 U.S.C. 801 et seq.) to engage in the type of activity that is carried out by the individual or entity with respect to a controlled substance on the schedule that is applicable to cannabidiol or marihuana, as applicable;
(2)
the term cannabidiol means—
(A)
the substance, cannabidiol, as derived from marihuana that has a delta-9-tetrahydrocannabinol level that is greater than 0.3 percent; and
(B)
the synthetic equivalent of the substance described in subparagraph (A);
(3)
the terms controlled substance, dispense, distribute, manufacture, marihuana, and practitioner have the meanings given such terms in section 102 of the Controlled Substances Act (21 U.S.C. 802), as amended by this Act;
(4)
the term covered institution of higher education means an institution of higher education (as defined in section 101 of the Higher Education Act of 1965 (20 U.S.C. 1001)) that—
(A)
(i)
has highest or higher research activity, as defined by the Carnegie Classification of Institutions of Higher Education; or
(ii)
is an accredited medical school or an accredited school of osteopathic medicine; and
(B)
is appropriately registered under the Controlled Substances Act (21 U.S.C. 801 et seq.);
(5)
the term drug has the meaning given the term in section 201(g)(1) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 321(g)(1));
(6)
the term medical research for drug development means medical research that is—
(A)
a preclinical study or clinical investigation conducted in accordance with section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) or otherwise permitted by the Department of Health and Human Services to determine the potential medical benefits of marihuana or cannabidiol as a drug; and
(B)
conducted by a covered institution of higher education, practitioner, or manufacturer that is appropriately registered under the Controlled Substances Act (21 U.S.C. 801 et seq.); and
(7)
the term State means any State of the United States, the District of Columbia, and any territory of the United States.